Association of Optimal Lamotrigine Serum Levels and Therapeutic Efficacy in Mood Disorders: A Systematic Review
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Purpose: The aim of the study was to appraise the current evidence on the optimal serum level for lamotrigine (LAM) in the treatment of mood disorders (major depressive disorder, bipolar disorder). Methods: Major databases were searched for randomized controlled trials, open-label trials, and observational studies reporting serum LAM levels in adult patients treated with LAM for mood disorders. Results: A total of 814 abstracts were screened and 24 articles were selected for full-text review. Seven studies (226 bipolar disorder and 17 major depressive disorder patients) including 1 randomized controlled trial (n = 43), 3 prospective (n = 53), and 3 retrospective (n = 147) studies met the study criteria with a study duration range from 6 to 96 weeks. Lamotrigine daily dosage varied from 25 to 425 mg/d among the studies. Studies reported inconsistent findings between LAM concentration and efficacy. Three studies did not identify a relationship between LAM levels and a significant improvement in mood symptoms. Two studies (n = 99) reported higher response rates with LAM serum levels of greater than 3.25 μg/mL and 1 study (n = 25) reported a wide therapeutic window of 5 to 11 μg/mL. Overall, LAM was well tolerated with no major significant adverse effects. Conclusions: Most studies showed a minimum LAM threshold level of 3 μg/mL in patients with mood disorders; however, the data are inconsistent regarding the therapeutic range for LAM. Based on the pooled data, there is inconsistent evidence to make conclusive recommendations on therapeutic LAM serum levels for mood improvement. Further studies including larger sample sizes are required to address this relevant clinical question.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lastly, we should also acknowledge the inconclusive evidence between association of lamotrigine serum levels and response which could contribute to inadequate therapeutic levels (Kumar et al., 2021).”
From Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis (2022) · cites this paper as Kumar et al., 2021
Citations
Cites
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Slim, K., Nini, E., Forestier, D., Kwiatkowski, F., Panis, Y., & Chipponi, J. (2003) · ANZ Journal of Surgery · doi:10.1046/j.1445-2197.2003.02748.x · Cited by 7,603 · cited 2×
“For the nonrandomized/observational studies, the methodological quality was assessed using Methodological Index for Non-Randomized Studies.17”
MethodCalabrese, J. R., Bowden, C. L., Sachs, G. S., Ascher, J. A., Monaghan, E., Rudd, G. D., & The Lamictal 602 Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0203 · Cited by 1,054
Bowden, C. L. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.4.392 · Cited by 658
Calabrese, J. R., Bowden, C. L., Sachs, G., Yatham, L. N., Behnke, K., Mehtonen, O.-P., Montgomery, P., Ascher, J., Paska, W., Earl, N., et al. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0906 · Cited by 635
Lim, K.-C., Ini, E. M. N., Orestier, D. A. F., Wiatkowski, F. A. K., & Anis, Y. V. P. (2003) · Cited by 449
Geddes, J. R., Calabrese, J. R., & Goodwin, G. M. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.048504 · Cited by 434
Lamotrigine Clinical Pharmacokinetics
Rambeck, B., & Wolf, P. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199325060-00003 · Cited by 244
Barbosa, L., Berk, M., & Vorster, M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0407 · Cited by 165
Cited by
Nuñez, N. A., Joseph, B., Pahwa, M., Kumar, R., Resendez, M. G., Prokop, L. J., Veldic, M., Seshadri, A., Biernacka, J. M., Frye, M. A., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.134 · Cited by 215
Self-citationThyroid Hormone Augmentation for Bipolar Disorder: A Systematic Review
Seshadri, A., Sundaresh, V., Prokop, L. J., & Singh, B. (2022) · Brain Sciences · doi:10.3390/brainsci12111540 · Cited by 25
Self-citationJoseph, B., Núñez, N. A., Kung, S., Voort, J. L. V., Pazdernik, V., Schak, K. M., Boehm, S. M., Carpenter, B., Johnson, E. K., Malyshev, G., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16081164 · Cited by 18
“Lamotrigine is an antiepileptic drug, which is also FDA-approved for the maintenance treatment of bipolar disorder [7].”
BackgroundSelf-citationEfficacy and safety of lamotrigine in pediatric mood disorders: A systematic review
Kumar, R., Garzon, J. F., Yuruk, D., Hassett, L. C., Saliba, M. T., Özger, C., Oztosun, C., Ahern, K. B., Athreya, A. P., Singh, B., et al. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13500 · Cited by 14
“003 kg/m(3)) of LAM in adults.(25) To date, no study has been conducted to review the evidence for effective serum levels of LAM treatment of PMD.”
BackgroundSelf-citationGlobal Trends in the Use of Pharmacotherapy for the Treatment of Bipolar Disorder
Yocum, A. K., & Singh, B. (2025) · Current Psychiatry Reports · doi:10.1007/s11920-025-01606-8 · Cited by 16
“There is some weak data regarding its efficacy in patients with BD and rapid cycling [33].”
Self-citation
Metadata
- Authors
- Kumar, R., Nuñez, N. A., Prokop, L. J., Veldic, M., Betcher, H., & Singh, B.
- Affiliations
- Guru Gobind Singh Medical College and Hospital (IN)
- Department of Psychiatry and Psychology, Mayo Clinic
- Mayo Clinic (US)
- Corresponding author
- Kumar, Rakesh
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2021-08-27
- Volume
- 41
- Issue
- 6
- Pages
- 681-686
- ISSN
- 0271-0749 (ISSN-L)
- 1533-712X
- OpenAlex
- W3197329166
- Cited by
- 16
- References
- 31
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 1 · 2023: 2 · 2022: 4
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- lamotrigine, serum drug concentration, therapeutic drug monitoring, mood disorders, bipolar disorder, major depressive disorder, treatment efficacy, therapeutic window, adverse effects
- MeSH terms
- Lamotrigine, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Major, Humans, Antipsychotic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of Optimal Lamotrigine Serum Levels and Therapeutic Efficacy in Mood Disorders: A Systematic Review. https://app.cochat.ai/papers/10.1097/jcp.0000000000001475
- The paper
- Kumar, R., Nuñez, N. A., Prokop, L. J., Veldic, M., Betcher, H., & Singh, B. (2021). Association of Optimal Lamotrigine Serum Levels and Therapeutic Efficacy in Mood Disorders: A Systematic Review. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000001475
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.